# MOONRAY-01 (NCT06586515)

> MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06586515
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer
- Interventions: LY3962673; Cetuximab; Gemcitabine; nab-paclitaxel; Oxaliplatin; leucovorin; Irinotecan; 5-fluorouracil
- Enrollment: 630
- Primary outcome: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
- Primary outcome: Phase 1a: Number of Participants with DLT
- Primary outcome: Phase 1a: Number of Participants with DLT Equivalent Toxicities
- Primary outcome: Phase 1b: Overall Response Rate (ORR)
- Primary outcome: Phase 1b: Best Overall Response (BOR)
- Primary outcome: Phase 1b: Duration of Response (DOR)
- Primary outcome: Phase 1b: Time to Response (TTR)
- Primary outcome: Phase 1b: Disease Control Rate (DCR)

## Indexed commentary on MOONRAY-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=moonray-01-nct06586515